BRPI0614524B8 - uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto - Google Patents
uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido compostoInfo
- Publication number
- BRPI0614524B8 BRPI0614524B8 BRPI0614524A BRPI0614524A BRPI0614524B8 BR PI0614524 B8 BRPI0614524 B8 BR PI0614524B8 BR PI0614524 A BRPI0614524 A BR PI0614524A BR PI0614524 A BRPI0614524 A BR PI0614524A BR PI0614524 B8 BRPI0614524 B8 BR PI0614524B8
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- hydrogen
- combination
- het
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 quinoline derivative compound Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto. a presente invenção refere-se ao uso de um composto para a fabricação de um medicamento para o tratamento de uma infecção bacteriana desde que a infecção bacteriana seja diferente de uma infecção micobacterina, o referido composto sendo um composto de fórmula (la) ou (lb) um sal de adição de ácido ou de base farmaceuticamente aceitável do mesmo, uma amina quaternária do mesmo, uma forma estereoquimicamente isomérica do mesmo, uma forma tautomérica do mesmo ou uma forma n-óxido do mesmo, em que r1 é hidrogênio, halo, haloalquila, ciano, hidróxi, ar, het, alquila, alquilóxi, alquiltio, alquiloxialquila, alquiltioaíquila, ar-alquila ou di (ar) alquila; p é 1, 2 ou 3; r2 é hidrogénio; alquila; hidróxi; mercapto; alquilóxi opcionalmente substituido; alquiloxialquilóxi; alquiltio; mono ou di (alquil) amino em que alquila pode ser opcionalmente substituida; ar; het ou um radical de fórmula (ii); r3 é alquila, ar, ar-alquila, het ou het-alquila; q é zero, 1, 2, 3 ou 4; x é uma ligação direta ou ch2; r4 e r5 cada independentemente são hidrogênio, alquila ou benzila; ou e r5 podem ser tomados juntos incluindo o n ao qual eles são fixados; r6 é hidrogênio ou um radical de fórmula; r7 é hidrogênio, alquila, ar ou het; r8 é hidrogênio ou alquila; r9 é oxo; ou e r9 juntos formam o radical -ch=ch-n=.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107159.5 | 2005-08-03 | ||
| EP05107159 | 2005-08-03 | ||
| PCT/EP2006/064856 WO2007014940A2 (en) | 2005-08-03 | 2006-07-31 | Quinoline derivatives as antibacterical agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0614524A2 BRPI0614524A2 (pt) | 2011-04-05 |
| BRPI0614524B1 BRPI0614524B1 (pt) | 2020-05-19 |
| BRPI0614524B8 true BRPI0614524B8 (pt) | 2021-05-25 |
Family
ID=35768940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0614524A BRPI0614524B8 (pt) | 2005-08-03 | 2006-07-31 | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8017606B2 (pt) |
| EP (1) | EP1912647B1 (pt) |
| JP (1) | JP5410753B2 (pt) |
| KR (1) | KR101337237B1 (pt) |
| CN (1) | CN101277695B (pt) |
| AR (1) | AR054889A1 (pt) |
| AU (1) | AU2006274879B2 (pt) |
| BR (1) | BRPI0614524B8 (pt) |
| CA (1) | CA2615901C (pt) |
| CY (1) | CY1114908T1 (pt) |
| DK (1) | DK1912647T3 (pt) |
| EA (1) | EA014832B1 (pt) |
| ES (1) | ES2437575T3 (pt) |
| HK (1) | HK1124233A1 (pt) |
| HR (1) | HRP20131116T1 (pt) |
| IL (1) | IL189141A (pt) |
| JO (1) | JO2952B1 (pt) |
| MX (1) | MX2008001602A (pt) |
| MY (1) | MY148241A (pt) |
| NO (1) | NO341247B1 (pt) |
| NZ (1) | NZ565283A (pt) |
| PL (1) | PL1912647T3 (pt) |
| PT (1) | PT1912647E (pt) |
| RS (1) | RS53065B (pt) |
| SI (1) | SI1912647T1 (pt) |
| TW (1) | TWI381839B (pt) |
| UA (1) | UA95916C2 (pt) |
| WO (1) | WO2007014940A2 (pt) |
| ZA (1) | ZA200801108B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005016890D1 (de) * | 2004-01-23 | 2009-11-12 | Janssen Pharmaceutica Nv | Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| WO2009091324A1 (en) * | 2008-01-14 | 2009-07-23 | Jyoti Chattopadhyaya | Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents |
| JP5246715B2 (ja) * | 2009-01-27 | 2013-07-24 | 独立行政法人科学技術振興機構 | 蛋白質架橋阻害剤およびその用途 |
| WO2010144102A1 (en) * | 2009-06-09 | 2010-12-16 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command | Pentafluorosulfanyl analogs of mefloquine |
| WO2013160431A1 (en) | 2012-04-27 | 2013-10-31 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| DK2841425T3 (en) | 2012-04-27 | 2016-06-27 | Janssen Pharmaceutica Nv | ANTIBACTERIAL QUINOLIN DERIVATIVES |
| KR20150070348A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제 |
| BR112015008308A2 (pt) | 2012-10-16 | 2017-12-05 | Janssen Pharmaceutica Nv | moduladores de quinolinila ligados por metileno do ror-gama-t |
| SG11201502935VA (en) | 2012-10-16 | 2015-09-29 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
| WO2014070760A1 (en) | 2012-10-30 | 2014-05-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of resazurin, or analogs thereof, for antibacterial therapy |
| JP6423423B2 (ja) | 2013-10-15 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｒｏｒγｔのアルキル結合キノリニルモジュレーター |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| BR112016008257A2 (pt) | 2013-10-15 | 2017-09-26 | Janssen Pharmaceutica Nv | moduladores de roryt de álcool quinolínico secundário |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| GB201904796D0 (en) * | 2019-04-04 | 2019-05-22 | Univ Sheffield | Antimicrobial agent |
| AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
| AR121682A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317491D0 (en) * | 1993-08-23 | 1993-10-06 | Fujisawa Pharmaceutical Co | New compound and a process for preparation thereof |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| US6376670B1 (en) * | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| GB9914486D0 (en) * | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
| GB9917408D0 (en) * | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
| SI2301544T1 (sl) * | 2002-07-25 | 2013-01-31 | Janssen Pharmaceutica, N.V. | Derivati kinolina kot vmesne spojine za mikobakterijske inhibitorje |
| DE50312598D1 (de) * | 2002-10-10 | 2010-05-20 | Morphochem Ag Komb Chemie | Neue verbindungen mit antibakterieller aktivität |
| DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| MXPA06005686A (es) * | 2003-11-20 | 2006-08-17 | Janssen Pharmaceutica Nv | 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa. |
| NZ547193A (en) * | 2003-12-05 | 2010-03-26 | Janssen Pharmaceutica Nv | 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| DE602005016890D1 (de) * | 2004-01-23 | 2009-11-12 | Janssen Pharmaceutica Nv | Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren |
| JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
-
2006
- 2006-07-18 JO JO2006233A patent/JO2952B1/en active
- 2006-07-31 KR KR1020087005066A patent/KR101337237B1/ko active IP Right Grant
- 2006-07-31 DK DK06778081.7T patent/DK1912647T3/da active
- 2006-07-31 BR BRPI0614524A patent/BRPI0614524B8/pt not_active IP Right Cessation
- 2006-07-31 US US11/997,182 patent/US8017606B2/en active Active
- 2006-07-31 EP EP06778081.7A patent/EP1912647B1/en active Active
- 2006-07-31 PL PL06778081T patent/PL1912647T3/pl unknown
- 2006-07-31 ES ES06778081.7T patent/ES2437575T3/es active Active
- 2006-07-31 EA EA200800501A patent/EA014832B1/ru unknown
- 2006-07-31 WO PCT/EP2006/064856 patent/WO2007014940A2/en active Application Filing
- 2006-07-31 CA CA2615901A patent/CA2615901C/en active Active
- 2006-07-31 SI SI200631705T patent/SI1912647T1/sl unknown
- 2006-07-31 PT PT67780817T patent/PT1912647E/pt unknown
- 2006-07-31 RS RS20130539A patent/RS53065B/en unknown
- 2006-07-31 NZ NZ565283A patent/NZ565283A/en not_active IP Right Cessation
- 2006-07-31 MX MX2008001602A patent/MX2008001602A/es active IP Right Grant
- 2006-07-31 CN CN200680036637XA patent/CN101277695B/zh not_active Expired - Fee Related
- 2006-07-31 JP JP2008524508A patent/JP5410753B2/ja not_active Expired - Fee Related
- 2006-07-31 UA UAA200801433A patent/UA95916C2/ru unknown
- 2006-07-31 AU AU2006274879A patent/AU2006274879B2/en not_active Ceased
- 2006-08-01 MY MYPI20063726A patent/MY148241A/en unknown
- 2006-08-02 TW TW095128223A patent/TWI381839B/zh active
- 2006-08-02 AR ARP060103371A patent/AR054889A1/es not_active Application Discontinuation
-
2008
- 2008-01-31 IL IL189141A patent/IL189141A/en active IP Right Grant
- 2008-02-01 ZA ZA200801108A patent/ZA200801108B/xx unknown
- 2008-02-25 NO NO20080955A patent/NO341247B1/no not_active IP Right Cessation
-
2009
- 2009-02-05 HK HK09101044.5A patent/HK1124233A1/xx not_active IP Right Cessation
-
2013
- 2013-11-22 HR HRP20131116TT patent/HRP20131116T1/hr unknown
- 2013-12-11 CY CY20131101116T patent/CY1114908T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0614524B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto | |
| BRPI0614493B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto | |
| BRPI0506400B8 (pt) | uso de um composto para a fabricação de um medicamento para o tratamento de tuberculose latente | |
| RS20090249A (en) | Spiroketone acetyl-coa carboxylase inhibotors | |
| ATE457988T1 (de) | A2a-adenosin-rezeptor-antagonisten | |
| ATE490958T1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
| WO2005070924A8 (en) | Substituted quinolines and their use as mycobacterial inhibitors | |
| BRPI0417268A (pt) | benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios | |
| BRPI0614099B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto e o referido composto | |
| BRPI0612498A8 (pt) | derivados de quinolina como agentes antibacterianos | |
| MY151030A (en) | Quinoline derivatives as antibacterial agents | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| TH80291A (th) | การรักษาวัณโรคแฝง | |
| TH80291B (th) | การรักษาวัณโรคแฝง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/05/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2786 DE 28-05-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |